Back to top

Image: Bigstock

Bayer AG

Read MoreHide Full Article

Bayer’s earnings beat the Zacks Consensus Estimate but sales missed the estimates in the third quarter of 2017. Sales at Consumer Health decreased, primarily due to a difficult U.S. market environment. Further, as part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell selected Crop Science businesses to BASF. With this agreement, the company will actively address the authorities’ possible concerns regarding the planned acquisition of Monsanto and facilitate a successful closing of the transaction by early 2018. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. However, the company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Yet, Bayer’s shares have outperformed the industry year to date.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Bayer Aktiengesellschaft (BAYRY) - free report >>

Published in